NDAORALTABLET
Approved
Jan 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
JENTADUETO (linagliptin and metformin hydrochloride) by Boehringer Ingelheim is dipeptidyl peptidase 4 inhibitors [moa]. Approved for dipeptidyl peptidase 4 inhibitor [epc]. First approved in 2012.
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JENTADUETO is a fixed-dose combination tablet containing linagliptin (a DPP-4 inhibitor) and metformin hydrochloride, approved in 2012 for type 2 diabetes management. It works by increasing insulin secretion in response to glucose and decreasing hepatic glucose production. The combination targets patients requiring dual-agent glycemic control.
$94MPart D
PeakStable
11.3 years to LOEProduct is in mature peak revenue phase with modest Part D utilization (~104k claims in 2023), indicating established but consolidated market position.
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®.
Started Nov 2013
36 enrolled
Healthy
Career Relevance
JENTADUETO offers moderate career opportunities within Boehringer Ingelheim's established diabetes franchise, though growth constraints from GLP-1/SGLT2 competition limit expansion scope. Roles are concentrated in commercial, medical affairs, and market access functions focused on defending mature market share against newer mechanisms.
Brand Manager
Worked on JENTADUETO at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.